{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:47Z","timestamp":1787003747344,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02296-1","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:33:58Z","timestamp":1747661638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improvement of iron status with elexacaftor tezacaftor ivacaftor therapy is associated with the correction of systemic inflammation and improvement of lung function: a one-year prospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Herv\u00e9","family":"Lobbes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Roux-Perceval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quitterie","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2296_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez, A., Daly, C., Vega-Hernandez, G., MacGregor, G. & Rubin, J. L. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J. Cyst. Fibros. 22, 607\u2013614 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann, H. & Ratjen, F. Cystic fibrosis. N. Engl. J. Med. 389, 1693\u20131707 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2296_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/0884533608323426","volume":"23","author":"A von Drygalski","year":"2008","unstructured":"von Drygalski, A. & Biller, J. Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency. Nutr. Clin. Pract. 23, 557\u2013563 (2008).","journal-title":"Nutr. Clin. Pract."},{"key":"2296_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcf.2012.10.001","volume":"12","author":"DJ Smith","year":"2013","unstructured":"Smith, D. J. et al. Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. J. Cyst. Fibros. 12, 303\u2013304 (2013).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/nu14030673","volume":"14","author":"H Lobbes","year":"2022","unstructured":"Lobbes, H. et al. Iron deficiency in cystic fibrosis: A Cross-Sectional Single-Centre study in a referral adult centre. Nutrients 14, 673 (2022).","journal-title":"Nutrients"},{"key":"2296_CR6","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2014-08-595256","volume":"125","author":"C Guida","year":"2015","unstructured":"Guida, C. et al. A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. Blood 125, 2265\u20132275 (2015).","journal-title":"Blood"},{"key":"2296_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","volume":"397","author":"SR Pasricha","year":"2021","unstructured":"Pasricha, S. R., Tye-Din, J., Muckenthaler, M. U. & Swinkels, D. W. Iron deficiency. Lancet 397, 233\u2013248 (2021).","journal-title":"Lancet"},{"key":"2296_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1752-8062.2012.00417.x","volume":"5","author":"AH Gifford","year":"2012","unstructured":"Gifford, A. H. et al. Iron homeostasis during cystic fibrosis pulmonary exacerbation. Clin. Transl. Sci. 5, 368\u2013373 (2012).","journal-title":"Clin. Transl. Sci."},{"key":"2296_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jcf.2014.03.007","volume":"13","author":"L Uijterschout","year":"2014","unstructured":"Uijterschout, L. et al. The value of soluble transferrin receptor and Hepcidin in the assessment of iron status in children with cystic fibrosis. J. Cyst. Fibros. 13, 639\u2013644 (2014).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcf.2014.03.012","volume":"14","author":"AH Gifford","year":"2015","unstructured":"Gifford, A. H. What is Hepcidin telling Us about the natural history of cystic fibrosis? J. Cyst. Fibros. 14, 155\u2013157 (2015).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ppul.20717","volume":"42","author":"R Fischer","year":"2007","unstructured":"Fischer, R., Simmerlein, R., Huber, R. M., Schiffl, H. & Lang, S. M. Lung disease severity, chronic inflammation, iron deficiency, and erythropoietin response in adults with cystic fibrosis. Pediatr. Pulmonol. 42, 1193\u20131197 (2007).","journal-title":"Pediatr. Pulmonol."},{"key":"2296_CR12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the Elexacaftor plus Tezacaftor plus Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394, 1940\u20131948 (2019).","journal-title":"Lancet"},{"key":"2296_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/cid\/ciac117","volume":"75","author":"AC Miller","year":"2022","unstructured":"Miller, A. C. et al. The rapid reduction of Infection-Related visits and antibiotic use among people with cystic fibrosis after starting Elexacaftor-Tezacaftor-Ivacaftor. Clin. Infect. Dis. 75, 1115\u20131122 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"2296_CR14","doi-asserted-by":"publisher","first-page":"175346662513147","DOI":"10.1177\/17534666251314706","volume":"19","author":"A Pepe","year":"2025","unstructured":"Pepe, A. et al. Elexacaftor\/tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study. Ther. Adv. Respir Dis. 19, 17534666251314706 (2025).","journal-title":"Ther. Adv. Respir Dis."},{"key":"2296_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000538606","volume":"42","author":"N Stastna","year":"2024","unstructured":"Stastna, N. et al. Improved nutritional outcomes and Gastrointestinal symptoms in adult cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor. Dig. Dis. 42, 361\u2013368 (2024).","journal-title":"Dig. Dis."},{"key":"2296_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","volume":"387","author":"A Lopez","year":"2016","unstructured":"Lopez, A., Cacoub, P. & Macdougall, I. C. Peyrin-Biroulet, L. Iron deficiency anaemia. Lancet 387, 907\u2013916 (2016).","journal-title":"Lancet"},{"key":"2296_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","volume":"133","author":"C Camaschella","year":"2019","unstructured":"Camaschella, C. Iron deficiency. Blood 133, 30\u201339 (2019).","journal-title":"Blood"},{"key":"2296_CR18","unstructured":"World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. (2011). https:\/\/apps.who.int\/iris\/handle\/10665\/85839"},{"key":"2296_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace, T. M., Levy, J. C. & Matthews, D. R. Use and abuse of HOMA modeling. Diabetes Care. 27, 1487\u20131495 (2004).","journal-title":"Diabetes Care"},{"key":"2296_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jcf.2021.05.010","volume":"21","author":"T Toin","year":"2022","unstructured":"Toin, T. et al. HOMA indices as screening tests for cystic fibrosis-related diabetes. J. Cyst. Fibros. 21, 123\u2013128 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen, J. A power primer. Psychol. Bull. 112, 155\u2013159 (1992).","journal-title":"Psychol. Bull."},{"key":"2296_CR22","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1038\/s41598-021-84041-y","volume":"11","author":"AH Gifford","year":"2021","unstructured":"Gifford, A. H. et al. A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends. Sci. Rep. 11, 4897 (2021).","journal-title":"Sci. Rep."},{"key":"2296_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ncp.10454","volume":"35","author":"LS Gettle","year":"2020","unstructured":"Gettle, L. S., Harden, A., Bridges, M. & Albon, D. Prevalence and risk factors for Iron deficiency in adults with cystic fibrosis. Nutr. Clin. Pract. 35, 1101\u20131109 (2020).","journal-title":"Nutr. Clin. Pract."},{"key":"2296_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cca.2006.11.021","volume":"378","author":"S Khalid","year":"2007","unstructured":"Khalid, S., McGrowder, D., Kemp, M. & Johnson, P. The use of soluble transferin receptor to assess iron deficiency in adults with cystic fibrosis. Clin. Chim. Acta. 378, 194\u2013200 (2007).","journal-title":"Clin. Chim. Acta"},{"key":"2296_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1378\/chest.121.1.48","volume":"121","author":"DW Reid","year":"2002","unstructured":"Reid, D. W., Withers, N. J., Francis, L., Wilson, J. W. & Kotsimbos, T. C. Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection. Chest 121, 48\u201354 (2002).","journal-title":"Chest"},{"key":"2296_CR26","first-page":"897","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","unstructured":"Centers for Disease Control and Prevention (CDC). Iron deficiency\u2013United States, 1999\u20132000. MMWR Morb Mortal. Wkly. Rep. 51, 897\u2013899 (2002).","journal-title":"MMWR Morb Mortal. Wkly. Rep."},{"issue":"3","key":"2296_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ppul.26805","volume":"59","author":"A James","year":"2024","unstructured":"James, A. et al. Analysis of iron status after initiation of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis. Pediatr. Pulmonol. 59(3), 669\u2013678. https:\/\/doi.org\/10.1002\/ppul.26805 (2024).","journal-title":"Pediatr. Pulmonol."},{"key":"2296_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","volume":"29","author":"KF Kernan","year":"2017","unstructured":"Kernan, K. F. & Carcillo, J. A. Hyperferritinemia and inflammation. Int. Immunol. 29, 401\u2013409 (2017).","journal-title":"Int. Immunol."},{"key":"2296_CR29","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss, G. & Goodnough, L. T. Anemia of chronic disease. N Engl. J. Med. 352, 1011\u20131023 (2005).","journal-title":"N Engl. J. Med."},{"key":"2296_CR30","doi-asserted-by":"publisher","unstructured":"Jia, S. et al. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis. J Cyst Fibros S1569-1993(24)00030\u20134 (2024). https:\/\/doi.org\/10.1016\/j.jcf.2024.03.002","DOI":"10.1016\/j.jcf.2024.03.002"},{"key":"2296_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry, P. J. et al. Triple therapy for cystic fibrosis Phe508del\u2013Gating and \u2013Residual function genotypes. N. Engl. J. Med. 385, 815\u2013825 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2296_CR32","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.3390\/ijms22126493","volume":"22","author":"E Nemeth","year":"2021","unstructured":"Nemeth, E. & Ganz, T. Hepcidin-Ferroportin interaction controls systemic Iron homeostasis. Int. J. Mol. Sci. 22, 6493 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2296_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jcf.2013.11.004","volume":"13","author":"AH Gifford","year":"2014","unstructured":"Gifford, A. H. et al. Iron supplementation does not worsen respiratory health or alter the sputum Microbiome in cystic fibrosis. J. Cyst. Fibros. 13, 311\u2013318 (2014).","journal-title":"J. Cyst. Fibros."},{"key":"2296_CR34","doi-asserted-by":"crossref","unstructured":"Ka\u0142u\u017cna-Czy\u017c, M., Grzybowska-Chlebowczyk, U., Wo\u015b, H. & Wi\u0119cek, S. Serum Hepcidin Level as a Marker of Iron Status in Children with Cystic Fibrosis. Mediators Inflamm 3040346 (2018). (2018).","DOI":"10.1155\/2018\/3040346"},{"key":"2296_CR35","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1016\/S2352-3026(21)00056-9","volume":"8","author":"EJ Zhao","year":"2021","unstructured":"Zhao, E. J., Cheng, C. V., Mattman, A. & Chen, L. Y. C. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. Lancet Haematol. 8, e365\u2013e375 (2021).","journal-title":"Lancet Haematol."},{"key":"2296_CR36","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1152\/ajplung.00391.2007","volume":"295","author":"S Moreau-Marquis","year":"2008","unstructured":"Moreau-Marquis, S. et al. The \u2206F508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L25\u2013L37 (2008).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2296_CR37","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz, L. et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46, 678\u2013684 (2014).","journal-title":"Nat. Genet."},{"key":"2296_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jcf.2012.05.002","volume":"11","author":"ZH Hoo","year":"2012","unstructured":"Hoo, Z. H. & Wildman, M. J. Intravenous iron among cystic fibrosis patients. J. Cyst. Fibros. 11, 560\u2013562 (2012).","journal-title":"J. Cyst. Fibros."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02296-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:34:00Z","timestamp":1747661640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2296"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02296-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Isabelle Durieu reports a relationship outside this work with the French Ministry of Health and with the Non Profit Organization \u201cVaincre la mucoviscidose\u201d that includes: funding grants from Zambon outside this work that includes: travel reimbursement. Prof. Isabelle Durieu reports a relationship with Vertex that includes: board membership outside this work. The other authors reports no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17394"}}